2025 life sciences IPOs followed a selective pattern similar to recent years, with activity concentrated in later-stage biotech and medtech companies that had de-risked assets or near-term clinical catalysts. The U.S. federal government shutdown introduced friction, slowing regulatory processes and U.S. Food and Drug Administration review timelines. These factors, coupled with competition from China-based companies with comparative advantages for development through proof-of-concept, significantly affected earlier-stage companies. Companies integrating AI and machine learning into R&D and drug discovery also drew significant investor interest.
Read the full article: 2025 Technology and Life Sciences IPO Report //
Source: https://www.lexology.com/library/detail.aspx?g=6218869c-ab09-4cc2-9ea2-036da13252ed